Valuation: Affimed N.V.

Market Cap 18.84M 21.61M 17.79M 16.16M 30.27M 2.07B 30.4M 213M 82.24M 1.05B 81.17M 79.37M 3.39B P/E 2022
-1.92x
P/E 2023 -0.8x
Enterprise Value -336K -386K -318K -288K -540K -37.01M -543K -3.8M -1.47M -18.81M -1.45M -1.42M -60.54M EV / Sales 2022
0.03x
EV / Sales 2023 4.69x
Free-Float
92.89%
Yield 2022 *
-
Yield 2023 -
1 week 0
Extreme 0.0001
0
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0.04
1 year 0
Extreme 1.0E-6
0.05
3 years 0
Extreme 1.0E-6
8.95
5 years 0
Extreme 1.0E-6
73.5
10 years 0
Extreme 1.0E-6
117.4
Manager TitleAgeSince
Chief Executive Officer 42 2024-09-02
Director of Finance/CFO 61 2023-12-30
Chief Executive Officer 65 2024-01-14
Director TitleAgeSince
Chairman 75 2006-12-31
Director/Board Member 71 2016-01-20
Director/Board Member 60 2020-08-03
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%0.00%-100.00% 1.64K
-0.31%+3.56%+46.40%+100.50% 70.89B
+0.39%+2.06%+40.91%+78.49% 62.32B
-2.98%-6.62%-17.15%+355.14% 27.07B
-2.94%-0.90%-0.47%-12.09% 24.78B
+0.71%+8.03%+27.22%-13.18% 20.59B
-1.26%-10.61%+170.72%+290.48% 15.52B
-0.74%+3.47%+43.56%+171.99% 14.49B
-1.21%-0.23%-8.94%+867.40% 14.14B
-1.11%-0.94%+20.13%+223.68% 12.35B
Average -0.92%+1.51%+32.24%+196.24% 26.22B
Weighted average by Cap. -0.74%+1.39%+35.58%+164.35%

Financials

2022 2023
Net sales 42.87M 49.16M 40.48M 36.76M 68.87M 4.72B 69.16M 485M 187M 2.4B 185M 181M 7.72B 13.91M 15.96M 13.14M 11.93M 22.35M 1.53B 22.45M 157M 60.73M 778M 59.94M 58.61M 2.5B
Net income -86M -98.63M -81.21M -73.74M -138M -9.46B -139M -973M -375M -4.81B -370M -362M -15.48B -106M -121M -100M -90.83M -170M -11.66B -171M -1.2B -462M -5.93B -456M -446M -19.07B
Net Debt -172M -197M -162M -148M -276M -18.94B -278M -1.95B -751M -9.63B -741M -725M -30.98B -19.18M -21.99M -18.11M -16.44M -30.81M -2.11B -30.94M -217M -83.71M -1.07B -82.62M -80.78M -3.45B
Logo Affimed N.V.
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
Employees
76
Date Price Change Volume
26-09-17 US$0.000100 0.00% 711
26-09-15 US$0.000100 0.00% 39,294
26-09-10 US$0.000100 0.00% 785

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AFMDQ Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!